Mark Bradley

Mark Bradley is the chief development officer of Alumis, bringing more than 25 years of experience in the biotechnology industry. Mark joins Alumis from Bristol Myers Squibb (BMS) where he has served as senior vice president & site head since BMS’s acquisition of MyoKardia, a precision medicine company focused on treating cardiovascular diseases. Prior to that, he held roles of increasing responsibility at MyoKardia, most recently as senior vice president, development. Before MyoKardia, Mark held roles of increasing responsibility at Genentech from 2004-2017, most recently serving as head, business management gRED clinical operations. Mark began his career at UCSF in public health research.